GlassScriptPhysician profile
Stephanie Ferrante
NPI 1285334987
$1,449.46
in general payments reported to CMS, 2019-2025
4 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $977 · Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $976.95 |
| Food and Beverage | $472.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novus Surgical Consultants | $781.51 | 2025 | |
| Arthrex, INC. | $462.45 | 2025 | |
| Stryker Corporation | $159.10 | 2025 | Mako, Triathlon |
| Heron Therapeutics, INC. | $46.40 | 2025 | Zynrelef |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Ferrante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.